辉瑞印度合资注射剂厂因洪水停产，新供应预计2028年中后期起分批恢复

Elsewhere in India, Pfizer operates a manufacturing facility in Goa that primarily produces small-molecule drugs and oral solids, as well as a sterile injectables plant in Visakhapatnam, Andhra Pradesh, that employs roughly 2,000 people. (FatCamera/iStock/Getty Images Plus)

A Pfizer joint venture in India that manufactures injectable chemotherapy drugs for U.S. cancer patients remains closed following severe flooding in July, with new supplies from the facility not expected to become available until mid-to-late 2028 under the company's best-case estimate.

The prolonged shutdown of the Zydus Hospira Oncology facility in Ahmedabad, Gujarat, threatens to compound existing shortages of chemotherapy drugs in the U.S., according to a recent report (PDF) from the American Society of Health-System Pharmacists (ASHP). The closure was first reported by Endpoints and confirmed to Fierce by Pfizer.

“On July 23, 2026, heavy monsoon rains severely flooded the Zydus Hospira Oncology Private Limited (ZHOPL) manufacturing facility in Gujarat, India,” a Pfizer spokesperson said in an emailed statement. The spokesperson said all approximately 150 employees at the site are safe and accounted for.

“The site remains closed as our teams continue comprehensive assessments across the facility to determine the full scope of work needed to safely resume operations,” the spokesperson explained.

“Given the extent of the damage to the facility, including the laboratories, medicine production areas, and manufacturing equipment, the current best-case estimate is that new supply will be available in a phased approach beginning in mid-to-late 2028,” Pfizer’s spokesperson told Fierce.

The plant, a joint venture between Pfizer and Zydus Cadila, has an annual production capacity of 7 million vials and supplies markets in the U.S., Europe, Australia, New Zealand, Japan, Canada and the Asia-Pacific region, according to Pfizer's website.

The prolonged closure is already affecting supplies of certain Pfizer chemotherapy products. ASHP's drug shortage database identifies manufacturing delays related to the flooding as a cause of shortages of cytarabine, irinotecan and bleomycin injections.

For certain presentations of cytarabine and irinotecan, Pfizer expects existing supplies to be depleted by the end of 2026 or in the first quarter of 2027, according to ASHP. Once those supplies run out, Pfizer's affected products are not expected to be available for the remainder of 2027.

Pfizer said it is “putting every effort behind restoring product supply,” while also “evaluating alternative sites within our global manufacturing network and third-party manufacturing options to help mitigate the impact on supply where possible.”

Elsewhere in India, Pfizer operates a manufacturing facility in Goa that primarily produces small-molecule drugs and oral solids, as well as a sterile injectables plant in Visakhapatnam, Andhra Pradesh, that employs roughly 2,000 people.

The Visakhapatnam facility has an annual production capacity of approximately 380 million vials, according to Pfizer.